Ranolazine in LQT3 Patients

Trial Profile

Ranolazine in LQT3 Patients

Phase of Trial: Phase II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Long QT syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Sep 2016 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.
    • 30 Dec 2015 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top